|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SH3GLB1 |
Gene summary for SH3GLB1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SH3GLB1 | Gene ID | 51100 |
| Gene name | SH3 domain containing GRB2 like, endophilin B1 | |
| Gene Alias | Bif-1 | |
| Cytomap | 1p22.3 | |
| Gene Type | protein-coding | GO ID | GO:0000045 | UniProtAcc | A0A087WW40 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51100 | SH3GLB1 | LZE2T | Human | Esophagus | ESCC | 1.92e-02 | 3.43e-01 | 0.082 |
| 51100 | SH3GLB1 | LZE4T | Human | Esophagus | ESCC | 2.57e-07 | 3.28e-01 | 0.0811 |
| 51100 | SH3GLB1 | LZE8T | Human | Esophagus | ESCC | 1.46e-12 | 1.89e-01 | 0.067 |
| 51100 | SH3GLB1 | LZE20T | Human | Esophagus | ESCC | 1.53e-05 | 5.54e-01 | 0.0662 |
| 51100 | SH3GLB1 | LZE22D1 | Human | Esophagus | HGIN | 1.47e-05 | 1.79e-01 | 0.0595 |
| 51100 | SH3GLB1 | LZE22T | Human | Esophagus | ESCC | 5.16e-09 | 2.29e-01 | 0.068 |
| 51100 | SH3GLB1 | LZE24T | Human | Esophagus | ESCC | 9.95e-20 | 6.67e-01 | 0.0596 |
| 51100 | SH3GLB1 | LZE21T | Human | Esophagus | ESCC | 3.42e-07 | 3.46e-02 | 0.0655 |
| 51100 | SH3GLB1 | LZE6T | Human | Esophagus | ESCC | 4.01e-06 | 3.08e-02 | 0.0845 |
| 51100 | SH3GLB1 | P1T-E | Human | Esophagus | ESCC | 2.33e-09 | 9.50e-01 | 0.0875 |
| 51100 | SH3GLB1 | P2T-E | Human | Esophagus | ESCC | 1.80e-39 | 6.46e-01 | 0.1177 |
| 51100 | SH3GLB1 | P4T-E | Human | Esophagus | ESCC | 7.76e-25 | 7.39e-01 | 0.1323 |
| 51100 | SH3GLB1 | P5T-E | Human | Esophagus | ESCC | 2.14e-36 | 9.61e-01 | 0.1327 |
| 51100 | SH3GLB1 | P8T-E | Human | Esophagus | ESCC | 3.36e-29 | 7.17e-01 | 0.0889 |
| 51100 | SH3GLB1 | P9T-E | Human | Esophagus | ESCC | 1.07e-12 | 5.82e-01 | 0.1131 |
| 51100 | SH3GLB1 | P10T-E | Human | Esophagus | ESCC | 1.14e-29 | 6.32e-01 | 0.116 |
| 51100 | SH3GLB1 | P11T-E | Human | Esophagus | ESCC | 7.21e-17 | 1.16e+00 | 0.1426 |
| 51100 | SH3GLB1 | P12T-E | Human | Esophagus | ESCC | 2.27e-94 | 2.19e+00 | 0.1122 |
| 51100 | SH3GLB1 | P15T-E | Human | Esophagus | ESCC | 5.64e-32 | 8.25e-01 | 0.1149 |
| 51100 | SH3GLB1 | P16T-E | Human | Esophagus | ESCC | 2.09e-24 | 3.21e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:19037493 | Liver | Cirrhotic | positive regulation of establishment of protein localization to mitochondrion | 21/4634 | 36/18723 | 1.80e-05 | 2.44e-04 | 21 |
| GO:0000045 | Liver | Cirrhotic | autophagosome assembly | 43/4634 | 99/18723 | 3.56e-05 | 4.32e-04 | 43 |
| GO:001050811 | Liver | Cirrhotic | positive regulation of autophagy | 51/4634 | 124/18723 | 4.25e-05 | 5.03e-04 | 51 |
| GO:1905037 | Liver | Cirrhotic | autophagosome organization | 44/4634 | 103/18723 | 4.74e-05 | 5.50e-04 | 44 |
| GO:19037473 | Liver | Cirrhotic | regulation of establishment of protein localization to mitochondrion | 25/4634 | 50/18723 | 1.01e-04 | 1.05e-03 | 25 |
| GO:0044088 | Liver | Cirrhotic | regulation of vacuole organization | 23/4634 | 45/18723 | 1.23e-04 | 1.22e-03 | 23 |
| GO:19039552 | Liver | Cirrhotic | positive regulation of protein targeting to mitochondrion | 18/4634 | 32/18723 | 1.38e-04 | 1.34e-03 | 18 |
| GO:1990928 | Liver | Cirrhotic | response to amino acid starvation | 23/4634 | 49/18723 | 6.06e-04 | 4.67e-03 | 23 |
| GO:1902115 | Liver | Cirrhotic | regulation of organelle assembly | 66/4634 | 186/18723 | 6.66e-04 | 5.04e-03 | 66 |
| GO:00009105 | Liver | Cirrhotic | cytokinesis | 62/4634 | 173/18723 | 7.13e-04 | 5.33e-03 | 62 |
| GO:19032143 | Liver | Cirrhotic | regulation of protein targeting to mitochondrion | 21/4634 | 44/18723 | 7.88e-04 | 5.79e-03 | 21 |
| GO:00328012 | Liver | Cirrhotic | receptor catabolic process | 15/4634 | 28/18723 | 9.91e-04 | 6.98e-03 | 15 |
| GO:004311211 | Liver | Cirrhotic | receptor metabolic process | 59/4634 | 166/18723 | 1.19e-03 | 8.07e-03 | 59 |
| GO:2000785 | Liver | Cirrhotic | regulation of autophagosome assembly | 18/4634 | 39/18723 | 2.93e-03 | 1.67e-02 | 18 |
| GO:0034198 | Liver | Cirrhotic | cellular response to amino acid starvation | 20/4634 | 46/18723 | 4.15e-03 | 2.22e-02 | 20 |
| GO:007259422 | Liver | HCC | establishment of protein localization to organelle | 299/7958 | 422/18723 | 1.06e-32 | 6.10e-30 | 299 |
| GO:000989622 | Liver | HCC | positive regulation of catabolic process | 335/7958 | 492/18723 | 3.83e-31 | 1.87e-28 | 335 |
| GO:003133122 | Liver | HCC | positive regulation of cellular catabolic process | 295/7958 | 427/18723 | 3.20e-29 | 1.45e-26 | 295 |
| GO:190382922 | Liver | HCC | positive regulation of cellular protein localization | 199/7958 | 276/18723 | 1.15e-23 | 2.62e-21 | 199 |
| GO:003164722 | Liver | HCC | regulation of protein stability | 211/7958 | 298/18723 | 2.29e-23 | 5.01e-21 | 211 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0414429 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
| hsa04144113 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
| hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| hsa0414010 | Esophagus | ESCC | Autophagy - animal | 101/4205 | 141/8465 | 7.60e-08 | 6.21e-07 | 3.18e-07 | 101 |
| hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| hsa0414015 | Esophagus | ESCC | Autophagy - animal | 101/4205 | 141/8465 | 7.60e-08 | 6.21e-07 | 3.18e-07 | 101 |
| hsa0414412 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
| hsa041406 | Liver | Cirrhotic | Autophagy - animal | 65/2530 | 141/8465 | 3.10e-05 | 2.47e-04 | 1.52e-04 | 65 |
| hsa0414413 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
| hsa0414011 | Liver | Cirrhotic | Autophagy - animal | 65/2530 | 141/8465 | 3.10e-05 | 2.47e-04 | 1.52e-04 | 65 |
| hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0414021 | Liver | HCC | Autophagy - animal | 99/4020 | 141/8465 | 3.08e-08 | 4.70e-07 | 2.61e-07 | 99 |
| hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0414031 | Liver | HCC | Autophagy - animal | 99/4020 | 141/8465 | 3.08e-08 | 4.70e-07 | 2.61e-07 | 99 |
| hsa0414427 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| hsa041409 | Oral cavity | OSCC | Autophagy - animal | 94/3704 | 141/8465 | 2.73e-08 | 2.38e-07 | 1.21e-07 | 94 |
| hsa04144112 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| hsa0414014 | Oral cavity | OSCC | Autophagy - animal | 94/3704 | 141/8465 | 2.73e-08 | 2.38e-07 | 1.21e-07 | 94 |
| hsa0414428 | Oral cavity | LP | Endocytosis | 121/2418 | 251/8465 | 1.89e-11 | 3.70e-10 | 2.38e-10 | 121 |
| hsa0414024 | Oral cavity | LP | Autophagy - animal | 55/2418 | 141/8465 | 4.54e-03 | 1.87e-02 | 1.20e-02 | 55 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SH3GLB1 | SNV | Missense_Mutation | rs533090731 | c.878N>G | p.Asn293Ser | p.N293S | protein_coding | tolerated(0.87) | benign(0.077) | TCGA-C8-A26Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | CR | |
| SH3GLB1 | SNV | Missense_Mutation | rs777019424 | c.413N>T | p.Thr138Met | p.T138M | protein_coding | deleterious(0.01) | probably_damaging(0.979) | TCGA-EK-A2RL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | taxol | PD | |
| SH3GLB1 | SNV | Missense_Mutation | c.254N>C | p.Arg85Thr | p.R85T | protein_coding | deleterious(0.03) | probably_damaging(0.962) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SH3GLB1 | SNV | Missense_Mutation | c.926N>A | p.Gly309Asp | p.G309D | protein_coding | tolerated(0.28) | benign(0.088) | TCGA-AA-3852-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
| SH3GLB1 | SNV | Missense_Mutation | novel | c.666N>T | p.Gln222His | p.Q222H | protein_coding | tolerated(0.41) | probably_damaging(0.978) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SH3GLB1 | SNV | Missense_Mutation | rs751120404 | c.618N>A | p.Phe206Leu | p.F206L | protein_coding | tolerated(0.79) | benign(0.007) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| SH3GLB1 | SNV | Missense_Mutation | c.1181N>G | p.Asn394Ser | p.N394S | protein_coding | tolerated(1) | probably_damaging(0.999) | TCGA-G4-6625-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| SH3GLB1 | SNV | Missense_Mutation | novel | c.427T>G | p.Phe143Val | p.F143V | protein_coding | tolerated(0.05) | probably_damaging(0.999) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| SH3GLB1 | SNV | Missense_Mutation | novel | c.940N>A | p.Ala314Thr | p.A314T | protein_coding | tolerated(0.27) | benign(0.007) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SH3GLB1 | SNV | Missense_Mutation | novel | c.133N>A | p.Leu45Ile | p.L45I | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |